← Back to Screener
MiNK Therapeutics, Inc. Common Stock (INKT)
Price$14.13
Favorite Metrics
Price vs S&P 500 (26W)-15.30%
Price vs S&P 500 (4W)30.96%
Market Capitalization$64.26M
All Metrics
Book Value / Share (Quarterly)$0.20
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.26
Price vs S&P 500 (YTD)13.41%
EPS (TTM)$-2.97
10-Day Avg Trading Volume0.05M
EPS Excl Extra (TTM)$-2.97
EPS (Annual)$-0.65
ROI (Annual)-127.04%
Cash / Share (Quarterly)$2.84
ROA (Last FY)-493.33%
EBITD / Share (TTM)$-2.93
Cash Flow / Share (Annual)$-1.26
P/B Ratio9.52x
P/B Ratio (Quarterly)10.56x
Net Income / Employee (Annual)$-1
Net Interest Coverage (TTM)-1.40x
ROA (TTM)-139.00%
EPS Incl Extra (Annual)$-0.65
Current Ratio (Annual)1.06x
Quick Ratio (Quarterly)1.04x
3-Month Avg Trading Volume0.21M
52-Week Price Return71.12%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$-0.39
P/S Ratio (Annual)93.13x
Asset Turnover (Annual)0.53x
52-Week High$76.00
EPS Excl Extra (Annual)$-0.65
26-Week Price Return-11.31%
Quick Ratio (Annual)1.04x
13-Week Price Return7.83%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)1.06x
Enterprise Value$56.077
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-3449.28%
Cash / Share (Annual)$2.84
3-Month Return Std Dev94.83%
Net Income / Employee (TTM)$-1
ROE (Last FY)-127.04%
EPS Basic Excl Extra (Annual)$-0.65
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.97
ROI (TTM)-168.87%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$-0.01
Price vs S&P 500 (52W)41.29%
Year-to-Date Return16.05%
5-Day Price Return12.82%
EPS Normalized (Annual)$-0.65
ROA (5Y Avg)-574.34%
Net Profit Margin (Annual)-3449.28%
Month-to-Date Return22.89%
Cash Flow / Share (TTM)$-0.72
EBITD / Share (Annual)$-0.66
Operating Margin (Annual)-3228.99%
LT Debt / Equity (Annual)0.00x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-2.97
P/B Ratio (Annual)6.29x
Book Value / Share (Annual)$0.71
Price vs S&P 500 (13W)7.15%
Beta0.52x
Revenue / Share (TTM)$0.00
ROE (TTM)-168.87%
52-Week Low$6.34
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.13
4.13
4.13
4.13
Industry Peers — Biological Products(89)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
INKTMiNK Therapeutics, Inc. Common Stock | — | — | — | — | $14.13 |
AMGNAmgen Inc | 5.13x | 9.95% | 73.30% | 2.93% | $349.39 |
GILDGilead Sciences Inc | 5.84x | 2.40% | 78.83% | 133.64% | $138.55 |
ARGXargenx SE American Depositary Shares | 12.46x | 89.56% | 150.91% | — | $828.35 |
BNTXBioNTech SE American Depositary Share | 8.75x | -11.81% | 84.21% | — | $102.12 |
BIIBBiogen Inc. Common Stock | 2.60x | 2.22% | 75.69% | -18.77% | $176.02 |
MRNAModerna, Inc. Common Stock | 11.02x | -39.93% | 70.32% | — | $54.68 |
NBIXNeurocrine Biosciences Inc | 4.49x | 21.45% | 98.18% | 2.31% | $128.41 |
EXELExelixis Inc | 4.96x | 6.85% | 96.39% | 31.10% | $44.38 |
TECHBio-Techne Corp. | 7.60x | 1.64% | 66.60% | -20.58% | $57.36 |
HALOHalozyme Therapeutics, Inc. | 5.74x | 37.55% | 83.62% | 22.89% | $66.64 |
About
MiNK Therapeutics is a clinical-stage biopharmaceutical company developing allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases. Its manufacturing platform enables scalable production of off-the-shelf cell therapies, with a pipeline of native and engineered iNKT programs.